Nanjing Well Pharmaceutical Group Co.,Ltd.

SHSE:603351 Stock Report

Market Cap: CN¥3.2b

Nanjing Well Pharmaceutical GroupLtd Balance Sheet Health

Financial Health criteria checks 5/6

Nanjing Well Pharmaceutical GroupLtd has a total shareholder equity of CN¥1.7B and total debt of CN¥423.9M, which brings its debt-to-equity ratio to 25.3%. Its total assets and total liabilities are CN¥2.3B and CN¥603.6M respectively. Nanjing Well Pharmaceutical GroupLtd's EBIT is CN¥166.9M making its interest coverage ratio 12. It has cash and short-term investments of CN¥169.9M.

Key information

25.3%

Debt to equity ratio

CN¥423.87m

Debt

Interest coverage ratio12x
CashCN¥169.87m
EquityCN¥1.68b
Total liabilitiesCN¥603.60m
Total assetsCN¥2.28b

Recent financial health updates

No updates

Recent updates

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

Jun 06
Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

Financial Position Analysis

Short Term Liabilities: 603351's short term assets (CN¥599.2M) exceed its short term liabilities (CN¥516.1M).

Long Term Liabilities: 603351's short term assets (CN¥599.2M) exceed its long term liabilities (CN¥87.5M).

Debt to Equity History and Analysis

Debt Level: 603351's net debt to equity ratio (15.2%) is considered satisfactory.

Reducing Debt: 603351's debt to equity ratio has increased from 8.4% to 25.3% over the past 5 years.

Debt Coverage: 603351's debt is well covered by operating cash flow (53.3%).

Interest Coverage: 603351's interest payments on its debt are well covered by EBIT (12x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 20:56
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanjing Well Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution